Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin A during withdrawal therapy for chronic migraine with medication overuse
NL-OMON22952Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of botulinum toxin type A in chronic migraine and medication overuse headache (MOH) (2 arms), sponsored by Leiden University Medical Center. Primary endpoints: Primary efficacy endpoint and Primary quality of life endpoint. Started Sep 2012; status: active, not recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
chronic migrainemedication overuse headache (MOH)
Beyond the preview
Go deeper on NL-OMON22952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22952.